Large-scale screening for ovarian cancer with a combination of transvaginal ultrasound and cancer antigen 125 is a feasible strategy that can accurately identify early cancers, a large UK trial of almost 203,000 women concluded.
The combination approach carried a sensitivity of 89 percent and specificity of 99.8 percent for both primary ovarian and tubal cancers. A comparison strategy that included only transvaginal ultrasound was just a sensitive but significantly less specific.
Although the two methods detected similar numbers of cancers, the ultrasound-only method identified significantly more borderline ovarian tumors, resulting in almost nine times as many surgeries (845 vs. 97), wrote the University of College London, and co-authors.
“This highlights an issue that has already become a significant problem in other cancer-screening strategies — the detection of cancers that may never have been diagnosed in an individual’s lifetime had [the patients] not been screened.”
Any cancer screening trial, no matter how impressive, needs to be viewed in light of the overdiagnosis issue, said the University of Utah, Salt Lake City.
“If you have to perform 30 surgeries to cure one cancer, but a patient dies from a surgical complication, you’re not really ahead in the game. In this case, we have almost 950 women undergoing surgery with general anesthetic, with all its attendant risks,” to find 87 cancers, 28 of which were borderline tumors. “Some of these would never have caused any health problems had they never been discovered.”
The four-year UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) comprised 202,638 postmenopausal women (mean age, 60 years). They were randomized to no screening, to annual screening with transvaginal ultrasound as a second-line test.
In the multimodal screening (MMS) group, women with an abnormal CA 125 had either a repeat CA 125 in 12 weeks or an ultrasound in six weeks, depending on their other risk factors. On the basis of these results, they could be returned to annual screening or slated for additional testing and clinical assessment.
In the ultrasound-only screening (USS) group, women with abnormal transvaginal ultrasound findings underwent a repeat ultrasound. Depending on these results, they were returned to the screening pool, scheduled for another ultrasound, or referred for clinical assessment.
In the MMS group, 9 percent of women required a repeat test, and 0.2 percent underwent surgery. In the USS group, 12 percent of women required a repeat test and 2 percent underwent surgery, a ratio of nine surgeries in the USS group for every one in the MSS group.
Of those who underwent surgery, 834 had benign ovarian pathology or normal ovaries, with a significantly higher occurrence in the USS group compared with the MSS group (787 vs. 47). Of these women, 24 (3 percent) experienced a major surgical complication, with the preponderance again occurring in the USS group (22 vs. 2).
Complications included six perforations of a hollow organ, two excessive hemorrhages requiring additional surgery, one readmission for portal site path with surgery to remove an endometriotic nodule and residual ovary, one pulmonary embolism, two deep vein thromboses, four wound dehiscences, one wound hematoma, two hernias, one significant case of ileus, one bowel obstruction, one bowel fistula, and two significant infections.
The two screening strategies detected similar numbers of ovarian or tubal malignancies (USS 45, MSS 42). But more borderline tumors were detected in the USS group (20 vs. 8). There was no significant between-group difference in the number of stage II borderline cancers.
For all primary ovarian and tubal cancers, MSS had a sensitivity of 89 percent, a specificity of 99.8 percent and a positive predictive value of 35 percent. USS had a sensitivity of 75 percent, a specificity of 98 percent and a positive predictive value of 3 percent. There were 19 surgeries per case of ovarian cancer in the USS group and 2 surgeries per cancer in the MSS group.
Although the study shows that women will participate in an annual prevalence screening program for ovarian cancer, it’s too early to draw conclusions about either strategy’s long-term effect, said an investigator in the Prostrate, Lung, Colorectal, and Ovarian Cancer Screening Trial. “Until we have some outcomes data, including data on mortality, we don’t really know about the overdiagnosis issue. It . . . gives us some important information, but as yet we can’t say which of the screening techniques — or no screening at all — is better.”